Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease with a worldwide prevalence of 25%. In the US, NAFLD and its subtype, nonalcoholic steatohepatitis (NASH), affect 30% and 5% of the population, respectively. Considering the ongoing obesity epidemic beginning in childhood, the rise in Diabetes and other factors, the prevalence of NAFLD along with the proportion of those with advanced liver disease is projected to continue to increase. This will have an important impact on public health reflected in healthcare costs, including impact on the need for liver transplantation, for which NASH is already close to becoming the most common indication.